InsidersTradesSigma
Follow the PROTAGONIST THERAPEUTICS, INC. share price and the full insider trade history of the company, a listed equity based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Market capitalisation: €9.7bn. The latest transaction was reported on 10 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: WILLIAM WADDILL. All data is openly available.
Analysts rate PROTAGONIST THERAPEUTICS, INC. Strong Buy (bullish), based on 13 analysts. Average price target: US$152.46.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
3 of 3 declarations
PROTAGONIST THERAPEUTICS, INC. is a biopharmaceutical company focused on developing innovative treatments for diseases related to the immune and endocrine systems. The company is listed on NASDAQ under the symbol PTGX.